Researchers at the Cornell University College of Veterinary Medicine (CVM) are a step closer to finding the fountain of youth ...
A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
A new mouse study shows high-dose aluminum adjuvant Imject Alum can induce liver fibrosis via inflammasome activation, ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback